Quick Answer
Kyverna Therapeutics, Inc. reported Stockholders Equity of $232.28 million for the year ending 2025.
- Kyverna Therapeutics, Inc. showed a decrease of -12.9% in Stockholders Equity from 2024 to 2025.
- This data is from Kyverna Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: -$84.61 million | Q2 2023: -$97.20 million | Q3 2023: -$111.81 million | Q1 2024: $360.99 million | Q2 2024: $333.51 million | Q3 2024: $302.71 million | Q1 2025: $224.01 million | Q2 2025: $184.38 million | Q3 2025: $151.95 million.
- Over the full 4 years of available data (2022 to 2025), Kyverna Therapeutics, Inc.'s Stockholders Equity has grown by 413.9%.
- Historical annual values: Fiscal year 2025: $232.28 million | Fiscal year 2024: $266.59 million | Fiscal year 2023: -$13.14 million | Fiscal year 2022: -$74.00 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: